590 related articles for article (PubMed ID: 25447989)
1. Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.
Chrysant SG; Chrysant GS
Curr Hypertens Rep; 2015 Jan; 17(1):511. PubMed ID: 25447989
[TBL] [Abstract][Full Text] [Related]
2. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
3. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
4. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
Feng YH; Fu P
Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
[TBL] [Abstract][Full Text] [Related]
5. Sequential RAAS blockade: is it worth the risk?
Persson F; Rossing P
Adv Chronic Kidney Dis; 2014 Mar; 21(2):159-65. PubMed ID: 24602465
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
7. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure.
Pugliese NR; Masi S; Taddei S
Heart Fail Rev; 2020 Jan; 25(1):31-42. PubMed ID: 31512149
[TBL] [Abstract][Full Text] [Related]
8. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
9. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Black HR
Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
[TBL] [Abstract][Full Text] [Related]
10. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin-aldosterone-blockade is associated with decreased use of antidepressant therapy in patients with type 1 diabetes and diabetic nephropathy.
Ahola AJ; Harjutsalo V; Forsblom C; Groop PH
Acta Diabetol; 2014 Aug; 51(4):529-33. PubMed ID: 24436029
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
13. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin-aldosterone system inhibitors in heart failure.
Shearer F; Lang CC; Struthers AD
Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
[TBL] [Abstract][Full Text] [Related]
16. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
Chrysant SG
Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
[TBL] [Abstract][Full Text] [Related]
17. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
Mansur SJ; Hage FG; Oparil S
Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
[TBL] [Abstract][Full Text] [Related]
18. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
19. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
